Literature DB >> 26659475

New Targets in the Drug Treatment of Heart Failure.

James A Iwaz1,2, Elizabeth Lee2, Hermineh Aramin2, Danilo Romero2, Navaid Iqbal2, Matt Kawahara2, Fatima Khusro2, Brian Knight2, Minal V Patel2, Sumita Sharma2, Alan S Maisel3,4.   

Abstract

Heart failure is a complex syndrome that has been a major contributor to readmissions into hospitals in the USA. Currently, a large number of medications are being used to treat the symptoms of the disease-digoxin, diuretics, renin-angiotensin-aldosterone system inhibitors, β-blockers, and vasodilators. There is no doubt that the given pharmaceutical therapy has been effective in lowering hospital readmission rates and prolonging life in individual chronic heart failure patients. Despite this, admission rates following heart failure hospitalization remain high, resulting in a substantial financial strain on healthcare institutions. Clearly, there is much room for improvement in heart failure therapy and management in reducing readmission rates. In this review, we address the unmet needs in the current drug treatment of chronic heart failure and describe novel drug targets that are currently under investigation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26659475     DOI: 10.1007/s40265-015-0498-3

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  108 in total

Review 1.  Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology.

Authors:  José López-Sendón; Karl Swedberg; John McMurray; Juan Tamargo; Aldo P Maggioni; Henry Dargie; Michal Tendera; Finn Waagstein; Jan Kjekshus; Philippe Lechat; Christian Torp-Pedersen
Journal:  Eur Heart J       Date:  2004-08       Impact factor: 29.983

2.  Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.

Authors:  Lisa C Costello-Boerrigter; William B Smith; Guido Boerrigter; John Ouyang; Christopher A Zimmer; Cesare Orlandi; John C Burnett
Journal:  Am J Physiol Renal Physiol       Date:  2005-09-27

3.  Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.

Authors:  Henry Krum; Barry Massie; William T Abraham; Kenneth Dickstein; Lars Kober; John J V McMurray; Ashkay Desai; Claudio Gimpelewicz; Albert Kandra; Bernard Reimund; Henning Rattunde; Juergen Armbrecht
Journal:  Eur J Heart Fail       Date:  2011-01       Impact factor: 15.534

Review 4.  Treatment of heart failure with normal ejection fraction: an inconvenient truth!

Authors:  Walter J Paulus; Joris J M van Ballegoij
Journal:  J Am Coll Cardiol       Date:  2010-02-09       Impact factor: 24.094

5.  The significance of circulating endothelin-1 as a predictor of coronary artery disease status and clinical outcomes following coronary artery catheterization.

Authors:  Fadia Mayyas; Mohammad Al-Jarrah; Khalid Ibrahim; Doaa Mfady; David R Van Wagoner
Journal:  Cardiovasc Pathol       Date:  2014-08-15       Impact factor: 2.185

6.  Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.

Authors:  A Rogier van der Velde; Lars Gullestad; Thor Ueland; Pål Aukrust; Yu Guo; Aram Adourian; Pieter Muntendam; Dirk J van Veldhuisen; Rudolf A de Boer
Journal:  Circ Heart Fail       Date:  2013-02-08       Impact factor: 8.790

7.  Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis.

Authors:  M Takata; H Tanaka; M Kimura; Y Nagahara; K Tanaka; K Kawasaki; M Seto; K Tsuruma; M Shimazawa; H Hara
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

8.  Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure.

Authors:  Hanna K Gaggin; Jackie Szymonifka; Anju Bhardwaj; Arianna Belcher; Benedetta De Berardinis; Shweta Motiwala; Thomas J Wang; James L Januzzi
Journal:  JACC Heart Fail       Date:  2014-01-25       Impact factor: 12.035

9.  Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jim Gong; Martin P Lefkowitz; Adel R Rizkala; Jean Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  Eur J Heart Fail       Date:  2013-04-05       Impact factor: 15.534

Review 10.  Ivabradine, coronary artery disease, and heart failure: beyond rhythm control.

Authors:  Pietro Scicchitano; Francesca Cortese; Gabriella Ricci; Santa Carbonara; Michele Moncelli; Massimo Iacoviello; Annagrazia Cecere; Michele Gesualdo; Annapaola Zito; Pasquale Caldarola; Domenico Scrutinio; Rocco Lagioia; Graziano Riccioni; Marco Matteo Ciccone
Journal:  Drug Des Devel Ther       Date:  2014-06-03       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.